Vivani Medical is an emerging biopharmaceutical company developing a portfolio of miniature, long-term, subdermal, drug implants with its proprietary NanoPortal™ technology.
Vivani’s lead candidate is NPM-119, a six-month GLP-1 receptor agonist implant candidate being developed to treat type 2 diabetes and obesity. NPM-119 is designed to optimize GLP-1 therapy by addressing two main challenges in achieving the full potential benefits of this therapy, medication non-adherence and tolerability.
Vivani plans to begin LIBERATE-1, a Phase 2 study assessing NPM-119’s safety and pharmacokinetic profile in type 2 diabetes patients, in 2023. In addition to an active control arm with Bydureon BCise, LIBERATE-1 will also evaluate NPM-119’s effect on both glycemic control and weight.
NanoPortal™ has broad potential application across a range of molecule types including peptide therapeutics. Vivani's current portfolio includes unpartnered implant candidates and feasibility programs with large pharma partners.
Cortigent is a subsidiary of Vivani developing targeted neurostimulation systems for improving the brain’s communication with specific parts of the body or to bypass injured body parts. Combining innovative neuroscience with proprietary microelectronics, software, and data processing capabilities, their technology has the potential to help patients regain control of body functions they lost to disease or injury. The applications currently under development are visual cortex stimulation to provide artificial vision and motor cortex stimulation to support motor skills recovery after a stroke.